ID: h-6ed7b5c8
Hypothesis
TREM2-APOE Axis Manipulation via APOE Lipidation for DAM Recruitment
Strongest mechanistic support among all hypotheses.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 5 support✗ 4 oppose
✓ All Quality Gates Passed
🧪 Overview
Strongest mechanistic support among all hypotheses. TREM2-TYROBP signaling for DAM transition well-established. AL002 Phase 2 readout (2025) will be pivotal. Skeptic correctly identifies that APOE4 may act downstream of TREM2, requiring genetic epistasis studies. Expert confirms TREM2 agonism has best tractability; ABCA1 agonists problematic due to hepatotoxicity. APOE protein replacement (Voyager) and TREM2 antibodies provide multiple development paths.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["Amyloid-beta Plaques<br/>Phospholipid Ligands"]
B["TREM2 Receptor<br/>Ligand Binding"]
C["TYROBP/DAP12<br/>ITAM Phosphorylation"]
D["SYK Kinase<br/>Activation"]
E["PLCG2<br/>IP3 + DAG Generation"]
F["Ca2+ Release<br/>Cytoskeletal Remodeling"]
G["Microglial Phagocytosis<br/>Plaque Compaction"]
A --> B
B --> C
C --> D
D --> E
E --> F
F --> G
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#1b5e20,stroke:#81c784,color:#81c784⚖️ Evidence
⚖️ Evidence Matrix5 supports4 contradicts
Supports
TREM2 R47H variant reduces microglial response to amyloid, impairing plaque localization
Supports
ABCA1 haploinsufficiency phenocopies APOE4 effects on microglial lipid metabolism
Contradicts
APOE4 microglial transcriptional changes are partially independent of TREM2 genotype
Contradicts
APOE4 carriers paradoxically show elevated DAM signature genes despite reduced plaque coverage
Contradicts
ABCA1 agonist CSK-925323 discontinued due to LXR-driven hepatotoxicity
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — TREM2-APOE
No curated PDB or AlphaFold mapping for TREM2-APOE yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for TREM2-APOE from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for TREM2-APOE.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↘
Falling
7d Momentum
▼ 1.1%
Volatility
Low
0.0045
Events (7d)
3
Price History
▼15.4%💾 Resource Usage
LLM Tokens
32,048
$0.0961
Total Cost
$0.0961
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF Trem2 is genetically ablated in 5xFAD mice and APOE lipidation is pharmacologically enhanced, THEN DAM recruitment and amyloid clearance effects will be completely abolished in Trem2 knockout anima | Trem2 knockout mice receiving APOE lipidation therapy will show equivalent amyloid burden and DAM gene expression to Trem2 knockout vehicle controls (no rescue | — no observation — | pending | 0.55 |
| IF APOE lipidation is enhanced via ABCA1 agonism (at sub-hepatotoxic doses) or APOE protein replacement therapy in 5xFAD mice, THEN measurable increases in DAM marker genes (Trem2, Clec7a, Itgax, Lpl) | ≥30% increase in DAM signature gene expression and ≥25% reduction in insoluble amyloid-beta plaques relative to vehicle-treated controls | — no observation — | pending | 0.65 |
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF APOE lipidation is enhanced via ABCA1 agonism (at sub-hepatotoxic doses) or APOE protein replacement therapy in 5xFAD mice, THEN measurable increases in DAM marker genes (Trem2, Clec7a, Itgax, Lpl) and reduced amyloid plaque burden will be observed within 8 weeks of treatment.
Predicted outcome: ≥30% increase in DAM signature gene expression and ≥25% reduction in insoluble amyloid-beta plaques relative to vehicle-treated controls
Falsification: No significant increase in DAM markers (fold-change <1.2, p>0.05) or no reduction in amyloid burden; any elevation of liver transaminases (ALT/AST >3× baseline) indicating hepatotoxicity
pendingconf 55%
IF Trem2 is genetically ablated in 5xFAD mice and APOE lipidation is pharmacologically enhanced, THEN DAM recruitment and amyloid clearance effects will be completely abolished in Trem2 knockout animals, demonstrating TREM2 is epistatic and required downstream of APOE.
Predicted outcome: Trem2 knockout mice receiving APOE lipidation therapy will show equivalent amyloid burden and DAM gene expression to Trem2 knockout vehicle controls (
Falsification: Rescue of amyloid pathology or DAM recruitment in Trem2 knockout mice despite APOE lipidation therapy, indicating APOE acts independently or upstream of TREM2
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.